ALPHAMAB ONCOLO.DL-000002
Research ALPHAMAB ONCOLO.DL-000002 (3NK) on Bullrun: market cap EUR 862.11M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker3NK
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 862.11M
- Financial periodFY2025
- RevenueCNY 566.24M
- Revenue growth-11.5%
- Net income-CNY 113.94M
- Free cash flow-CNY 153.48M
- Gross margin88.8%
Valuation Snapshot
latest market cap is EUR 862.11M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 566.24M | -CNY 113.94M | -CNY 153.48M | 88.8% | -0.12 | CNY 258.82M | CNY 122.98M | CNY 1.71B |
| FY2024 | CNY 640.08M | CNY 166.34M | CNY 190.56M | 90.6% | 0.17 | CNY 1.11B | CNY 185.96M | CNY 1.83B |
| FY2023 | CNY 218.77M | -CNY 210.59M | -CNY 239.02M | 74.8% | -0.22 | CNY 1.09B | CNY 257.08M | CNY 1.67B |
| FY2022 | CNY 166.85M | -CNY 325.72M | -CNY 429.96M | 73.5% | -0.35 | CNY 1.07B | CNY 345.39M | CNY 1.56B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 862.11M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ALPHAMAB ONCOLO.DL-000002's market cap?
ALPHAMAB ONCOLO.DL-000002's market capitalization is EUR 862.11M.
What does ALPHAMAB ONCOLO.DL-000002 do?
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand.